232 related articles for article (PubMed ID: 28064104)
41. Effect of microporation on passive and iontophoretic delivery of diclofenac sodium.
Patel H; Joshi A; Joshi A; Stagni G
Drug Dev Ind Pharm; 2015; 41(12):1962-7. PubMed ID: 25758411
[TBL] [Abstract][Full Text] [Related]
42. Antisense oligonucleotides in therapy for neurodegenerative disorders.
Evers MM; Toonen LJ; van Roon-Mom WM
Adv Drug Deliv Rev; 2015 Jun; 87():90-103. PubMed ID: 25797014
[TBL] [Abstract][Full Text] [Related]
43. Development of an efficient transdermal delivery system of small interfering RNA using functional peptides, Tat and AT-1002.
Uchida T; Kanazawa T; Takashima Y; Okada H
Chem Pharm Bull (Tokyo); 2011; 59(2):196-201. PubMed ID: 21297299
[TBL] [Abstract][Full Text] [Related]
44. Transdermal delivery of antisense compounds.
Brand RM; Iversen PL
Adv Drug Deliv Rev; 2000 Oct; 44(1):51-7. PubMed ID: 11035197
[TBL] [Abstract][Full Text] [Related]
45. Nanotechnologies and controlled release systems for the delivery of antisense oligonucleotides and small interfering RNA.
Fattal E; Barratt G
Br J Pharmacol; 2009 May; 157(2):179-94. PubMed ID: 19366348
[TBL] [Abstract][Full Text] [Related]
46. Targeted delivery of antisense oligonucleotides and siRNAs into mammalian cells.
Sioud M
Methods Mol Biol; 2009; 487():61-82. PubMed ID: 19301642
[TBL] [Abstract][Full Text] [Related]
47. Designing chemically modified oligonucleotides for targeted gene silencing.
Deleavey GF; Damha MJ
Chem Biol; 2012 Aug; 19(8):937-54. PubMed ID: 22921062
[TBL] [Abstract][Full Text] [Related]
48. Transdermal iontophoresis of flufenamic acid loaded PLGA nanoparticles.
Malinovskaja-Gomez K; Labouta HI; Schneider M; Hirvonen J; Laaksonen T
Eur J Pharm Sci; 2016 Jun; 89():154-62. PubMed ID: 27131608
[TBL] [Abstract][Full Text] [Related]
49. Polyplex gene delivery modulated by redox potential gradients.
Soundara Manickam D; Oupický D
J Drug Target; 2006 Sep; 14(8):519-26. PubMed ID: 17050118
[TBL] [Abstract][Full Text] [Related]
50. ENA oligonucleotides as therapeutics.
Koizumi M
Curr Opin Mol Ther; 2006 Apr; 8(2):144-9. PubMed ID: 16610767
[TBL] [Abstract][Full Text] [Related]
51. Types of RNA therapeutics.
Goleij P; Babamohamadi M; Rezaee A; Sanaye PM; Tabari MAK; Sadreddini S; Arefnezhad R; Motedayyen H
Prog Mol Biol Transl Sci; 2024; 203():41-63. PubMed ID: 38360005
[TBL] [Abstract][Full Text] [Related]
52. Delivery of a classical antihypertensive agent through the skin by chemical enhancers and iontophoresis.
Nair A; Reddy C; Jacob S
Skin Res Technol; 2009 May; 15(2):187-94. PubMed ID: 19622129
[TBL] [Abstract][Full Text] [Related]
53. Topical iontophoretic delivery of ionizable, biolabile aciclovir prodrugs: A rational approach to improve cutaneous bioavailability.
Chen Y; Alberti I; Kalia YN
Eur J Pharm Biopharm; 2016 Feb; 99():103-13. PubMed ID: 26686649
[TBL] [Abstract][Full Text] [Related]
54. Controlled delivery of antisense oligonucleotides: a brief review of current strategies.
Zhao X; Pan F; Holt CM; Lewis AL; Lu JR
Expert Opin Drug Deliv; 2009 Jul; 6(7):673-86. PubMed ID: 19552611
[TBL] [Abstract][Full Text] [Related]
55. Improvement of dermatitis by iontophoretically delivered antisense oligonucleotides for interleukin-10 in NC/Nga mice.
Sakamoto T; Miyazaki E; Aramaki Y; Arima H; Takahashi M; Kato Y; Koga M; Tsuchiya S
Gene Ther; 2004 Feb; 11(3):317-24. PubMed ID: 14737092
[TBL] [Abstract][Full Text] [Related]
56. Modulated iontophoretic delivery of small and large molecules through microchannels.
Kumar V; Banga AK
Int J Pharm; 2012 Sep; 434(1-2):106-14. PubMed ID: 22633929
[TBL] [Abstract][Full Text] [Related]
57. Non-Invasive Transdermal Delivery of Antisense Oligonucleotides with Biocompatible Ionic Liquids.
Toyofuku K; Wakabayashi R; Kamiya N; Goto M
ACS Appl Mater Interfaces; 2023 Jul; 15(28):33299-33308. PubMed ID: 37405761
[TBL] [Abstract][Full Text] [Related]
58. What's Next for Gastrointestinal Disorders: No Needles?
Urbanska AM; Karagiannis ED; Au AS; Dai SY; Mozafari M; Prakash S
J Control Release; 2016 Jan; 221():48-61. PubMed ID: 26646543
[TBL] [Abstract][Full Text] [Related]
59. LNA-antisense rivals siRNA for gene silencing.
Jepsen JS; Wengel J
Curr Opin Drug Discov Devel; 2004 Mar; 7(2):188-94. PubMed ID: 15603252
[TBL] [Abstract][Full Text] [Related]
60. Combined effect of low-frequency ultrasound and iontophoresis: applications for transdermal heparin delivery.
Le L; Kost J; Mitragotri S
Pharm Res; 2000 Sep; 17(9):1151-4. PubMed ID: 11087051
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
